Chronic Idiopathic Thrombocytopenic Purpura
Conditions
Brief summary
This study evaluates the safety and efficacy of 6 weeks dosing Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura Patients. All of the subjects in this study receive Hetrombopag.
Interventions
Sponsors
Jiangsu HengRui Medicine Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Inclusion Criteria: 1. Confirmed diagnosis of chronic ITP,a peripheral blood smear or bone marrow examination should support the diagnosis of ITP with no evidence of other causes of thrombocytopenia. 2. Patients had a platelet count of less than 30,000/µL both in the screening period and baseline. 3. Subjects who are refractory or have relapsed after at least one prior ITP therapy. 4. Previous therapy for ITP including rescue must have been completed at least 2 weeks prior to randomization. 5. Subjects treated with maintenance immunosuppressive therapy must be receiving a dose that has been stable for at least 1 month. 6. A complete blood count (CBC), within the reference range, with the following exceptions. * Platelets \<30×109/L is required for inclusion . * Hemoglobin: females and males 10.0 g/dl are eligible for inclusion. * Absolute neutrophil count (ANC) ≥1500/µL (1.5×109/L) is required for inclusion. 7.PT result no exceed normal by more than ±3s,APTT result no exceed normal by more than ±10s. 8.Female subjects have a negative result with HCG testing in the screening period and baseline. *
Exclusion criteria
1. Patients with any prior history of arterial or venous thrombosis，or diagnosis as Thrombophilia. 2. Subjects diagnosed with tumor. 3. Have pre-existing cardiac disease within the last 3 months.No arrhythmia known to increase the risk of thrombolic events (e.g. atrial fibrillation), or patients with a Corrected QT interval (QTc) \>450msec or QTc \>480 for patients with a Bundle Branch Block. 4. Female subjects who are nursing or pregnant at screening or pre-dose on baseline. 5. Treatment with thrombopoietin or an investigational drug within 30 days or five half-lives (whichever is longer) preceding the first dose of study medication. 6. Treatment with Rituximab or Splenectomy within the lat 6 months. 7. Subjects who have previously received eltrombopag or any other thrombopoietin receptor agonist within 30 days or five half-lives (whichever is longer). 8. Subject has consumed aspirin, aspirin-containing compounds, salicylates, anticoagulants, quinine or non-steroidal anti-inflammatories (NSAIDs) for \>3 consecutive days within 2 weeks of the study start and until the end of the study. 9. Any laboratory or clinical evidence for HIV infection.Any clinical history for hepatitis C infection; chronic hepatitis B infection; or any evidence for active hepatitis at the time of subject screening.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The number of subjects with adverse events as a measure of safety and tolerability. | From Day 1 to Day 70. |
Countries
China
Contacts
Primary ContactYu Hu, Ph.D
Backup ContactHeng Mei, Ph.D
Outcome results
None listed